Key Highlights

● Glaukos offered an initial 2027 sales view of about $1 billion.

● Third-quarter net sales reached a record $211.0 million versus $168 million expected.

● The 2026 sales outlook was raised to a range of $775 million to $785 million.

● Epioxa generated $53 million in Revenue against a $17 million consensus.

Glaukos (NYSE:GKOS) gave investors their first glimpse of 2027, pointing to sales of about $1 billion, and paired it with a record quarter that sent the eye-care company's shares soaring.

The number that changed the conversation

Quarterly beats move stocks; long-range targets can reset them. Glaukos did both on Thursday. Alongside a record third quarter, the eye-care company offered an initial view of 2027 sales of about $1 billion, giving investors a concrete figure to anchor their forecasts to well beyond the current year.

The stock surged on Thursday, October 29, trading at $241.01 at 3:40pm according to market data and ranking among the most-talked-about names in the S&P MidCap 400. Different sources measured the move at different points in the day, but every account showed a powerful advance that built from the morning into the afternoon.

From $775 million to $1 billion

The 2027 view looks even more striking alongside the near-term guidance. Glaukos raised its 2026 sales outlook to a range of $775 million to $785 million. Going from that range to roughly $1 billion the following year implies a substantial step up in sales, and it signals management's confidence that its newer products can keep driving growth.

For a medical technology company, crossing $1 billion in annual sales is a milestone that tends to change how it is perceived, moving it into a different tier of the industry.

The record quarter behind it

The early 2027 view did not arrive in a vacuum. Third-quarter net sales reached a record $211.0 million, well above the $168 million analysts expected, according to one report, and the company swung to a profit. Epioxa was the star, generating $53 million in revenue against a $17 million consensus.

That combination gave the 2027 outlook credibility. A forecast of rapid growth is easier for investors to believe when the company has just delivered a quarter that far exceeded what was expected.

Health care's big day

Glaukos' surge was part of a broad rally in health care, the best-performing sector in the S&P 500 on Thursday. Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) climbed after beating estimates, and one report grouped Glaukos with other health care standouts such as Teladoc (NYSE:TDOC) and Bausch Health (NYSE:BHC).

The wider market was split. The Nasdaq Composite fell 365.13 points to 26,184.72 and the S&P 500 slipped 23.59 points to 7,720.39 as Alphabet (NASDAQ:GOOGL) suffered its worst day since its 2004 IPO, wiping out roughly $500 billion in value. Small caps and much of the rest of the market rallied, with the Russell 2000 rising 28.71 points to 2,859.22.

One market strategist summed up the mood: "There's plenty of other places to go with your money outside of the AI trade that have pretty decent prospects." Medical technology with visible growth fit that description.

How investors use long-range targets

Most companies guide one year at a time. When management offers a figure for the following year this early, analysts typically use it to recalibrate their models, often pushing estimates higher. It also creates a public benchmark that the company will be measured against for the next year or more, which raises the stakes for execution.

What to watch

The early 2027 view of about $1 billion now becomes the yardstick for Glaukos. Investors will track each Quarterly Report for evidence that the company is on pace, and any revision to that figure, up or down, will be closely scrutinised.

Epioxa's adoption curve will be central, given how far it exceeded expectations this quarter. The fourth quarter will also test whether Glaukos can land within its raised 2026 range of $775 million to $785 million, setting up the leap into 2027.